T1	Concept 422 429	glycine
T2	Concept 435 441	serine
T3	Concept 458 473	acidic residues
T4	Concept 474 487	glutamic acid
T5	Concept 496 509	aspartic acid
R1	is-a Arg1:T4 Arg2:T3	
R2	is-a Arg1:T5 Arg2:T3	
T6	Action 408 418	enrichment
R3	target Arg1:T6 Arg2:T1	
R4	target Arg1:T6 Arg2:T2	
R5	target Arg1:T6 Arg2:T4	
R6	target Arg1:T6 Arg2:T5	
T7	Concept 636 646	Tupanvirus
T8	Concept 622 630	passages
T9	Concept 614 621	several
R7	has-property Arg1:T8 Arg2:T9	
R8	in-context Arg1:T8 Arg2:T7	
T10	Concept 662 668	mutant
T11	Concept 669 680	Guarani DNA
R9	has-property Arg1:T11 Arg2:T10	
T12	Action 692 700	decrease
R10	subject Arg1:T12 Arg2:T11	
R11	target Arg1:T12 Arg2:T11	
R12	causes Arg1:T8 Arg2:T12	
T13	Concept 706 712	CTD 4A
T14	Concept 717 723	CTD 4E
T15	Concept 731 738	defects
T16	Action 742 749	binding
T17	Action 742 749	binding
T18	Action 742 749	binding
T19	Action 742 749	binding
R13	subject Arg1:T16 Arg2:T14	
T20	Concept 753 759	O-MAD2
T21	Concept 764 770	C-MAD2
R14	target Arg1:T16 Arg2:T20	
R15	subject Arg1:T19 Arg2:T13	
R16	target Arg1:T19 Arg2:T21	
R17	subject Arg1:T18 Arg2:T14	
R18	target Arg1:T18 Arg2:T21	
R19	subject Arg1:T17 Arg2:T13	
R20	target Arg1:T16 Arg2:T20	
R21	causes Arg1:T16 Arg2:T15	
R22	causes Arg1:T18 Arg2:T15	
R23	causes Arg1:T19 Arg2:T15	
R24	causes Arg1:T17 Arg2:T15	
T23	Concept 16 27;28 38	recombinant SARS-CoV-2
T24	Concept 43 51	SARS-CoV
T25	Concept 70 81;82 86	recombinant ACE2
T27	Concept 115 125	293T cells
T28	Concept 87 94	protein
R25	is-a Arg1:T25 Arg2:T28	
T29	Concept 58 66	proteins
T30	Concept 52 57	spike
R26	has-property Arg1:T29 Arg2:T30	
R27	has-part Arg1:T24 Arg2:T29	
R28	has-part Arg1:T23 Arg2:T29	
T31	Action 104 114	expressing
R29	subject Arg1:T31 Arg2:T25	
R30	target Arg1:T31 Arg2:T27	
T26	Concept 0 12	Measurements
R31	in-context Arg1:T26 Arg2:T29	
R32	in-context Arg1:T26 Arg2:T25	
T32	Concept 28 38	SARS-CoV-2
T33	Concept 43 51	SARS-CoV
T34	Concept 195 199	ACE2
T35	Action 167 174	binding
T36	Concept 159 166	similar
R33	subject Arg1:T35 Arg2:T33	
T37	Action 167 174	binding
R34	subject Arg1:T37 Arg2:T32	
R35	has-property Arg1:T35 Arg2:T36	
R36	has-property Arg1:T37 Arg2:T36	
R37	in-context Arg1:T36 Arg2:T34	
T38	Concept 189 194	human
R38	in-context Arg1:T34 Arg2:T38	
T39	Action 126 135	confirmed
R39	subject Arg1:T39 Arg2:T31	
R40	subject Arg1:T39 Arg2:T26	
R42	target Arg1:T39 Arg2:T35	
R41	target Arg1:T39 Arg2:T37	
T22	Concept 551 558	library
T40	Concept 542 550	original
R43	has-property Arg1:T22 Arg2:T40	
T41	Action 526 534	compared
T42	Concept 519 525	rounds
R44	target Arg1:T41 Arg2:T40	
R45	subject Arg1:T41 Arg2:T42	
R46	in-context Arg1:T6 Arg2:T41	
T43	Concept 797 817	amino acid positions
T44	Concept 783 786	HLA
T45	Concept 787 792	types
R47	in-context Arg1:T45 Arg2:T44	
T46	Concept 861 865	JIA,
T47	Concept 866 873	uveitis
T48	Concept 897 905	diseases
T49	Concept 886 896	autoimmune
R48	in-context Arg1:T48 Arg2:T49	
T50	Concept 773 779	number
R49	in-context Arg1:T50 Arg2:T45	
T51	Action 847 857	associated
R50	subject Arg1:T51 Arg2:T50	
R51	target Arg1:T51 Arg2:T46	
R52	target Arg1:T51 Arg2:T47	
R53	target Arg1:T51 Arg2:T48	
T52	Action 847 857	associated
R54	subject Arg1:T52 Arg2:T43	
R55	target Arg1:T52 Arg2:T46	
R56	target Arg1:T52 Arg2:T47	
R57	target Arg1:T52 Arg2:T48	
T53	Concept 325 335	SARS-CoV-2
T54	Concept 321 324	new
R58	has-property Arg1:T53 Arg2:T54	
T55	Concept 360 376	transmissibility
T57	Concept 380 388	SARS-CoV
T58	Concept 360 376	transmissibility
R59	has-property Arg1:T57 Arg2:T55	
R60	has-property Arg1:T53 Arg2:T58	
*	same-as T55 T58
R61	entails Arg1:T39 Arg2:T58	
